How Scientists Made The First Gene-Editing Treatment For A Baby

Last month, a baby got the world’s first personalized gene-editing treatment. What will this mean for millions of others with genetic diseases?

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Speaker 00

  WNYC is supported by Bayer. Science is about asking questions, testing, trying again. It's not easy, but it's relentless. It evolves, and that's why science delivers. Learn more at sciencedelivers.com.

• 0:14Ira Flatow?

  Science Friday is supported by MathWorks, creator of MATLAB and Simulink software for technical computing and model-based design. MathWorks, accelerating the pace of discovery in engineering and science. Learn more at mathworks.com.

• 0:31Flora Lichtman?

  Hey, this is Flora Lichtman, and you're listening to Science Friday.

• 0:37Flora Lichtman?

  Today in the podcast, the story of a medical breakthrough many years in the making.

• 0:43Speaker 03

  One of my biggest fears in this whole process has been giving false hope. And so I wanted to be honest about all the things that could go wrong.

• 0:55Flora Lichtman?

  Last month, an historic first. Scientists created the first personalized gene-edited treatment for a baby who was born with a rare, life-threatening genetic disorder. After three doses, the baby's health significantly improved. So how does this gene-editing treatment work? What are the risks? And what does this breakthrough mean for the 30 million people in the US who have a rare genetic disease with no available treatments? To help get some answers, I'm joined by the physician scientists who led this research, Dr. Kieran Musunuru, professor of translational research at the University of Pennsylvania, and Dr. Rebecca Aronsnicholas, assistant professor of pediatrics and genetics at the Children's Hospital of Philadelphia and the University of Pennsylvania.

• 1:39Flora Lichtman?

  Welcome to you both to Science Friday.

• 1:42Speaker 04

  Thank you so much for having us.

• 1:43Speaker 03

  Yeah, thanks for having us.

• 1:45Flora Lichtman?

  Rebecca, let's start with your patient, KJ. Tell us a little bit about him and how he became the first baby to get this treatment that you all developed.

• 1:55Speaker 03

  Yeah, so KJ was born last summer. And unfortunately, within the first two days of life, he became quite sick. He had a very, very high level of a chemical in his blood called ammonia. And so the ammonia was causing KJ to be very sleepy and not feed very well. And this is a huge medical emergency because unless you can get rid of that ammonia, the baby is at risk of having permanent brain injury. And unfortunately, a high number of infants that are born with this type of disease die very early on in the neonatal period.

• 2:27Flora Lichtman?

  And do we know what was causing it? What was the illness?

• 2:30Speaker 03

  Yeah, so the illness is something called a urea cycle disorder. So when your urea cycle essentially helps you get rid of that ammonia. It helps you break down protein properly so you can get rid of that pneumonia that can build up and be toxic. And he has a specific genetic change that causes one step of his urea cycle to not work. In this case, it's the step called CPS1, and so he has something called CPS1 deficiency. Essentially, all that means is he has a genetic change that converts his urea cycle into a non-functional cycle. So ammonia will build up whenever he is sick or whenever he eats too much protein.

• 3:04Flora Lichtman?

  Kieran, how did you come into this?

• 3:07Speaker 04

  So Rebecca and I have been working for several years trying to figure out the best way to help patients like this, these very sick patients who have missing or broken enzymes in the liver that cause these conditions, urea cycle disorders. And we've been using a particular type of gene editing called CRISPR. Effectively, it can actually make changes to the genetic code. It can actually correct misspellings. So we've been experimenting with using this technology to try to figure out how to correct misspellings. And so we were able to fairly quickly craft a gene editing solution that was tailored just for KJ.

• 3:47Speaker 04

  Now, this is very important because many patients who have these particular diseases, they have a unique variant that they may not share with anyone else in the world. And so that was pretty much the case with KJ. And so we had to make a bespoke editing solution just for him. So that was one challenging aspect of trying to do this for KJ. The other challenging aspect is he was very, very sick. And even something as benign as a common cold that most of us would just shrug off could be life threatening for him. And it was clear this was going to continue happening. And if anything, it was just going to get worse over time. And the only prospect of fixing this long term is a liver transplant. It's a very crude way of

• 4:29Speaker 04

  Replacing that a broken enzyme or that missing enzyme by replacing the whole liver.

• 4:34Flora Lichtman?

  The whole liver.

• 4:34Speaker 04

  Yeah, that whole liver will have the the proper enzyme. And the problem with that is, you know, it's not 100% safe and it's particularly risky if you're doing it in a very young child. And of course, sometimes there's not a match available. And and all that time, there's risk of of ammonia levels rising with any little stressor. Um, and causing permanent damage to the brain or even coma or even death. So the clock was ticking. We had to do this quickly.

• 4:57Flora Lichtman?

  Well, that's what I wanted to, how quickly did you have to do it? What was your timeline?

• 5:01Speaker 03

  Yeah. So we wanted to do it as quickly as we possibly could, but in a way that was still safe. Um, and we often have to wait until an infant is is big enough to have a liver transplant. And oftentimes that that takes it about the time until a baby turns one. And so we thought that if we could come up with an editing solution. Um, before that first birthday, we we would have the potential of maybe helping a baby like KJ. And so, given the complexity of trying to do this for the first time, including manufacturing a drug, making sure that it was safe. Making sure we had all the proper approvals from the Food and Drug Administration. That this would definitely take us, you know, eight months, nine months at least to get to that point. And that was if everything went perfectly right.

• 5:45Speaker 03

  Um, and so I set a very ambitious timeline, thinking that we would absolutely go over that timeline. And so I said, we need a drug in hand by the time he turns seven months old. But I'm very happy to say that we actually got the approval from the the Food and Drug Administration. To administer this therapy a week ahead of schedule. So so much of this story happened because so many people stepped up to help us. And everybody worked around the clock, nights, weekends, like putting everything else on hold to try to make that very aggressive timeline.

• 6:19Flora Lichtman?

  What were the conversations with KJ's parents like? I mean, what were the risks and how did you talk them through it?

• 6:25Speaker 03

  Yeah, they were remarkable, I will say. I had a very candid first conversation with the family. I essentially told them, I have no idea if this is going to work. I have no idea if we're even going to really get to a point where we can manufacture a drug to even try for your child. And I was honest also, I said, I have no idea, it could do harm. One of my biggest fears in this whole process has been giving false hope. And so I wanted to be honest about all the things that could go wrong, both in the development process, but also after dosing. And so in that first conversation, they took it all in. They looked at me and said, we know that this might not work. We know that this might have no benefit for our child, but we think the science is important to advance.

• 7:08Speaker 03

  And we realize that this could have implications and benefits beyond our son. And so we fully support you working on this in a research capacity and to keep moving this forward. In parallel, we continue the gold standard clinical care that any child with CPS1 deficiency would receive. And this included listing him for a liver transplant, actually at an early age, at about five months of age because he was so severe. So the research efforts were going on in parallel with the clinical efforts, but they became full partners in this.

• 7:39Flora Lichtman?

  Well, I mean, aside from false hope and that it wouldn't work at all, what were the risks around dosing or unintended consequences?

• 7:49Speaker 04

  So the way this treatment works is you have the two components of CRISPR. We wrap them up in what you can think of as soap bubbles, very, very, very tiny soap bubbles. And literally billions of these little soap bubbles all put together in this little solution that you end up putting into the body intravenously through an infusion over about two hours. And once this therapy hits the bloodstream, it very quickly gets taken up by the liver. So, so the job of the liver is to clean things out of the blood. So pretty much anything you put into the blood will get taken up by the liver to some degree. So we were able to take advantage of that in these little soap bubbles. They take the components of The gene editing therapy right into the liver cells. And once there, they start to do their job and make the correction.

• 8:35Speaker 04

  And that actually is a pretty safe process. The biggest risk is there being an allergic reaction. The other issue that can arise is that there's actually a lot of stress on the liver. And so it can have some injury. And we were unsure exactly what to expect because no treatment like this has ever been given to a child before. Much less an infant. It's been given to adults, I'd say several hundred adults by now. And in general, it's proven to be quite safe.

• 9:05Flora Lichtman?

  There's clinical trials, right? For adult gene editing treatments.

• 9:08Speaker 04

  Exactly, there are several clinical trials underway. So that gave us some reassurance that it would probably be safe in a patient like KJ. But we didn't know and a baby's not simply a young adult. It can be a very, very different situation.

• 9:20Flora Lichtman?

  So for this to work, do you need every single cell in the liver to be changed?

• 9:28Speaker 03

  I think it depends on the underlying disease that you're trying to treat. For some rare diseases and some common diseases, yes, you're going to have to correct every cell in the liver. But for most of our metabolic disorders, we know that if you can correct a small fraction of the cells, that there should be a therapeutic benefit.

• 9:47Flora Lichtman?

  Okay, and I know that there's a GPS attached. And so presumably they're going to the right place to snip the right thing. But do they ever make mistakes? And is that a concern?

• 9:58Speaker 04

  So that is a possibility with this kind of technologies. The gene editing technology can occasionally get fooled and go to the wrong place and potentially make a change. Now, this is something we're obviously very, very, very careful about. And we did quite a lot of work beforehand to KJ to make sure that this kind of thing wouldn't happen. And so one interesting feature, I would say about this particular case is that KJ underwent genetic testing immediately after birth, once it was clear he was sick, to try to identify the genetic change that was responsible for his disease. And that's become quite a routine over the last few years. But because of that, we actually had the entirety of his genome sequence.

• 10:37Speaker 04

  And so we were able to actually use that information to analyze the GPS address that we're using in the treatment and make sure that for his individual genome, for his code, that it was unlikely that it was going to go anywhere other than where it should go.

• 10:55Flora Lichtman?

  How did KJ respond to the treatment?

• 10:58Speaker 03

  Yeah, so we all watched him very, very carefully for the couple hours over which his first infusion ran. And while we were all very nervous, he actually slept through the entire thing. He did great.

• 11:11Flora Lichtman?

  And is it permanent? Or do you expect that KJ would get follow-up injections as he gets older?

• 11:18Speaker 03

  It's a great question. We don't know, because this has never been given to a baby or an infant before, whether that change will be durable. We anticipate that it would. Because if you make that correction of that specific genetic variant that's misspelled, as the liver cells grow and divide, they will pass on that correction to the new liver cells. And we know that going from a six-month-old baby to a full-grown adult, his liver is going to grow and divide a ton. So we anticipate that that change will be passed on, but only time will tell. And so we will continue to watch him very carefully.

• 11:54Flora Lichtman?

  After the break, can this approach be scaled from one baby to millions of patients with rare diseases?

• 12:01Speaker 03

  If KJ is the only patient that is treated with this type of approach, then we failed in what we're trying to do.

• 12:12Speaker 00

  Science Friday is supported by PBS, presenting Going Wild. If you love learning about the natural world and meeting the scientists who help us understand it, be sure to check out the new season of Going Wild with Dr. Ray Wynn Grant. It's the chart-topping and Webby award-winning podcast from the folks at Nature on PBS, now with a video companion series. In this season of Going Wild, host acclaimed wildlife ecologist Dr. Ray Wynn Grant heads out into the field to explore the animals, people, and stories that make nature worth saving. Stops include a hibernating black bear den in Arkansas and an underwater shipwreck site off the Florida coast. If you're looking for a place to start, check out the season's debut episode, where Ray joins beloved biologist and influencer Jordan

• 12:55Speaker 00

  King in the Florida Everglades to learn about his unlikely journey into science and how to study a wetland when it's not very, well, wet. So don't miss out. Follow Going Wild with Dr. Ray Wengrant on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. WNYC is supported by Bear. Every day in America, science delivers, not just in the headlines, but in the moments that matter most. Science is a journey, one of curiosity, persistence, and progress. It's about asking questions, testing, learning, and improving again and again. Science delivers harvests that feed families, tools that help farmers grow more with less, and new ways to protect land for generations to come.

• 13:38Speaker 00

  Let's keep asking, keep testing, keep discovering, so science can keep delivering. Learn more at sciencedelivers.com.

• 13:45Speaker 05

  Support for Science Friday comes from the Heising Simons Foundation. Unlocking knowledge, opportunity, and possibilities. More at hsfoundation.org.

• 14:00Flora Lichtman?

  You know, we know that rare diseases often get overlooked by pharmaceutical companies because there's no financial incentive. Where did the money come from to develop this?

• 14:11Speaker 04

  So, the majority of the funding came from the United States National Institutes of Health, which is the biggest funder of biomedical research, not just in the country, but the world. But I would also say that we had a lot of academic and industry partners who came together to actually manufacture the drug and do the studies that needed to be done, so that it would be acceptable, from the perspective of the Food and Drug Administration, the FDA, to actually be able to give it to a patient like KJ. And they just stepped up and volunteered on their own to contribute to this project. And so, it's very hard to say exactly how much the entire effort cost.

• 14:52Speaker 04

  But between the federal funding from the National Institutes of Health, the NIH, and the in-kind contributions from the companies, that was a vast majority of the support that made this possible.

• 15:05Flora Lichtman?

  I mean, we're talking about, you know, a solution for one patient, right? And a ton of resources marshaled for one patient. Is it possible to scale this? And what are the challenges that go along with that?

• 15:18Speaker 03

  Yeah, I think it's essential that we try to scale this. If KJ is the only patient that is treated with this type of approach, then we failed in what we're trying to do. And so what we are really working to do is to move from personalized therapies to robust clinical trials where you have groups of patients who might each have their own individual genetic variant. But you can then essentially develop a different version of a gene editing drug to treat a variety of patients, but in a formal, what we call platform trial. And through those types of formal trials, we'll be able to really measure whether or not these types of drugs work and whether or not they're safe.

• 16:02Speaker 03

  And once you have those definitive clinical trials, these can become approved therapies. So what we're really trying to do is build a platform approach with formal clinical trials to get these to become approved therapies.

• 16:15Flora Lichtman?

  So this came out of significant NIH investment over years. How are the cuts to the NIH affecting the future of your work? And in your view, the future of developing other sort of breakthrough medical treatments like this one?

• 16:33Speaker 04

  So I think the biggest problem right now is the uncertainty. Right? So there have been cuts and there have been grants that have been terminated. It's affected a lot of our colleagues. We've been fortunate in that nothing we are doing has been affected yet. But you know, if the budget is slashed or what's known as indirect funding, which is sort of extra funding that comes from the NIH to support infrastructure. If that gets scaled back, it will hurt what we are trying to do. There's no doubt about it. The infrastructure is very important. You need institutional support. You need a regulatory team. You need clinical trial infrastructure. You need nursing staff who are trained to be able to administer experimental therapies to patients. And so those are just a few examples of everything that needs to go

• 17:18Speaker 04

  into an effort like this one. And so the future of funding is absolutely critical to what we're trying to do and what we hope to do and what we hope others will be able to do.

• 17:29Flora Lichtman?

  I mean, to me, as a layperson who covers this, but is not a scientist, it really feels like a stunning discovery. What is it like for you all?

• 17:42Speaker 03

  It has been

• 17:46Speaker 03

  one of the most emotional, challenging and exciting years of my life of trying to get this program to move forward since KJ was born last summer. I'll be honest, there have been points that I have been incredibly terrified.

• 18:02Speaker 03

  It is amazing to have the opportunity to try to advance this transformational science into patients for the first time. But with that, I'll be honest, there's times where we were just scared that we didn't know what the outcome would be. We didn't know what the next 24 hours would bring. And so it has been a very exciting but very overwhelming process, I will be honest.

• 18:26Flora Lichtman?

  One more question for you all. How do you feel like this story has been covered in the press?

• 18:30Speaker 03

  Yeah, I feel that the story has been covered well by a lot of really talented and well-meaning journalists, right?

• 18:39Flora Lichtman?

  Well-meaning, oh no.

• 18:41Speaker 03

  No, I don't, I don't mean this in a bad way. I mean this in a good way. This is a this is a complex approach to trying to treat a patient, right? There's a lot of science, there's a lot of medicine. There's a lot of specifics about an ultra rare disease that that no one has ever heard of. I have to tell you, it has been amazing to hear in the popular press, people talking about the urea cycle, which is a metabolic geneticist, you know, warms my heart that people can actually know that that cycle exists now, right? I think that in a story like this, where all of us want a perfect ending, I think it has been easy for some media outlets to jump to the conclusion that KJ is cured.

• 19:24Speaker 03

  And we have been very careful to never use that word. Because in reality, this is more of a treatment than a cure at this point in time. We think we made his incredibly severe urea cycle disorder less severe. But we still are caring for him on a regular basis and making sure that we keep him safe. So I think it's really important as we speak with the rare disease community, when we speak with other families, that everyone is aware that this Is what I hope is a step in the right direction. But we have to be honest about what we know and what we don't know. And anytime you treat a single patient, it's really hard to make definitive conclusions about how well something worked, or even how safe something is. And the only way

• 20:08Speaker 03

  we're really going to know how well these therapies work is by doing larger trials in a formal clinical trial setting. And so that's why we're really trying to push towards that next step, so that we can really understand as a community, what these drugs are capable of doing.

• 20:25Flora Lichtman?

  I want to thank you both for this very thoughtful conversation.

• 20:29Speaker 03

  Thank you.

• 20:30Speaker 04

  Thank you so much.

• 20:31Flora Lichtman?

  Dr. Kieran Musanuru, professor for translational research at the University of Pennsylvania, and Dr. Rebecca Aaron's Nicholas, assistant professor of pediatrics and genetics at the Children's Hospital of Philadelphia and the University of Pennsylvania.

• 20:46Flora Lichtman?

  Thanks for listening. Don't forget to rate and review us if you like the show. And you can always leave us a comment on this segment on Spotify. We'd love to hear from you. Today's episode was produced by D. Peter Schmidt. I'm Flora Lichtman. Thanks for listening.